

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [001-31326](#)

OMB APPROVAL	
OMB Number:	3235-0080
Expires:	March 31, 2018
Estimated average burden hours per response:	1.7

Issuer: [Eloxx Pharmaceuticals, Inc.](#)

Exchange: [Nasdaq Stock Market LLC](#)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: [950 Winter Street](#)
[Waltham MASSACHUSETTS 02451](#)

Telephone number: [781-577-5300](#)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

[Common stock](#)

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)
- 17 CFR 240.12d2-2(a)(2)
- 17 CFR 240.12d2-2(a)(3)
- 17 CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, [Nasdaq Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2024-03-20 By Aravind Menon Hearings Advisor
Date Name Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024, Eloxx Pharmaceuticals, Inc.

The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the securities of Eloxx Pharmaceuticals, Inc., effective at the opening of the trading session on April 1, 2024.

On April 11, 2023, Nasdaq Listing Qualifications staff (Staff) notified Eloxx Pharmaceuticals, Inc. (Company) that it determined to delist the Company based on its noncompliance with Rule 5550(b)(2). On April 18, 2023, the Company exercised its right to appeal the Staff determination to the Listing Qualifications Hearings Panel (Panel) pursuant to Rule 5815. A Panel hearing was held on May 18, 2023. On June 2, 2023, the Panel issued a decision to continue listing the Company securities provided certain conditions were met. On October 12, 2023, the Panel issued a decision to delist the shares of the Company due to the Company failure to regain compliance with Rule 5550(b)(2). On October 26, 2023, the Company exercised its right to appeal the Panel decision to the Nasdaq Listing and Hearing Review Council (Council) pursuant to Rule 5820(a). On December 21, 2023, the Council issued a decision that affirmed the Panel decision to delist the Company securities. On February 7, 2024, the Company was provided notice that the Nasdaq Board of Directors declined to call the Council decision for review pursuant to Rule 5825(a). The Staff determination to delist the Company units and rights became final on February 7, 2024.